^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
AL2846
i
Other names: AL2846, AL-2846, AL 2846
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Advenchen, Sino Biopharm
Drug class:
c-MET inhibitor
Related drugs:
2ms
A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis (clinicaltrials.gov)
P1/2, N=22, Terminated, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N=192 --> 22 | Trial completion date: Dec 2024 --> Feb 2024 | Recruiting --> Terminated; sponsor adjusts its research and development strategy
Enrollment change • Trial completion date • Trial termination
|
NF1 (Neurofibromin 1)
|
NF1 mutation
|
AL2846
2ms
A Clinical Study of AL2846 Capsule Combined With Gemzar Injection in the Treatment of Advanced Pancreatic Cancer (clinicaltrials.gov)
P1/2, N=34, Completed, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
New P1/2 trial • Metastases
|
gemcitabine • AL2846
6ms
A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=135, Active, not recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
New P1 trial • Metastases
|
PD-L1 (Programmed death ligand 1)
|
cisplatin • pemetrexed • benmelstobart (APL-502) • AL2846
11ms
Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy. (clinicaltrials.gov)
P3, N=518, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
New P3 trial • Metastases
|
docetaxel • benmelstobart (APL-502) • AL2846
over2years
A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis (clinicaltrials.gov)
P1/2, N=192, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
NF1 (Neurofibromin 1)
|
NF1 mutation
|
AL2846
over2years
A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis (clinicaltrials.gov)
P1/2, N=192, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Clinical • New P1/2 trial
|
NF1 (Neurofibromin 1)
|
NF1 mutation
|
AL2846
over3years
A Study of AL2846 Versus Zoledronic Acid in Subjects With Advanced Non-Small Cell Lung Cancer With Bone Metastasis (clinicaltrials.gov)
P2, N=60, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting | Initiation date: Apr 2020 --> Sep 2020
Clinical • Enrollment open • Trial initiation date
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • FGFR (Fibroblast Growth Factor Receptor)
|
zoledronic acid • AL2846
4years
A Study of AL2846 Versus Zoledronic Acid in Subjects With Advanced Non-Small Cell Lung Cancer With Bone Metastasis (clinicaltrials.gov)
P2, N=60, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Clinical • New P2 trial
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • FGFR (Fibroblast Growth Factor Receptor)
|
zoledronic acid • AL2846
Share via
